期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 21, 期 8, 页码 1013-1023出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2021.1889509
关键词
Myasthenia gravis; acetylcholine receptor; muscle-specific kinase; lipoprotein receptor-related protein 4; IVIG; biosimilar; autoimmune disease; immunosuppressant
Myasthenia gravis is an antibody-mediated disease managed by untargeted immunomodulatory agents. Rituximab, a monoclonal antibody, is a promising option for patients with muscle-specific kinase antibodies or refractory disease. Further studies are needed to assess its comparative efficacy and optimal regimen in MG.
Introduction: Myasthenia gravis (MG) is an antibody-mediated disease with diverse serology and clinical presentation. Currently, MG is managed by untargeted immunomodulatory agents. About 15% patients are refractory to these therapies. Several novel and targeted treatments are on the horizon. Rituximab, a monoclonal antibody, is reported to be highly effective with widespread oof-label usage in MG, particularly in patients with antibody against muscle-specific kinase or refractory disease. However, a recent trial showed negative results. Compared to conventional oral immunosuppressive therapies used in MG, Rituximab has several benefits. Regular hematological monitoring is not required though serious side effects can occur. Current status of Rituximab in MG and newer immunosuppressants is discussed. Areas explored: Biologic features, clinical effectiveness, safety profile, and newer preparations of Rituximab. Expert opinion: Rituximab provides a promising option for management of MG, particularly in patients with muscle-specific kinase antibodies or those with refractory disease. Several knowledge gaps remain due to scarcity of data from randomized controlled studies. Despite lack of regulatory approval Rituximab has found widespread usage in MG. Large, well-designed studies are needed to assess the comparative efficacy of Rituximab and its optimal regimen in MG.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据